1. Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma. 1995. 12:1–21.
Article
2. Bracken MB. Methylprednisolone and acute spinal cord injury: an update of the randomized evidence. Spine. 2001. 26:S47–S54.
3. Carlson GD, Gorden CD, Nakazawa S, Wada E, Smith JS, LaManna JC. Sustained spinal cord compression: part II: effect of methylprednisolone on regional blood flow and recovery of somatosensory evoked potentials. J Bone Joint Surg Am. 2003. 85:95–101.
4. Fernandez E, Pallini R, Marchese E, Talamonti G. Experimental studies on spinal cord injuries in the last fifteen years. Neurol Res. 1991. 13:138–159.
Article
5. Hulbert RJ, Moulton R. Why do you prescribe methylprednisolone for acute spinal cord injury? A Canadian perspective and a position statement. Can J Neurol Sci. 2002. 29:236–239.
6. Hurlbert RJ. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg. 2000. 93:Suppl 1. S1–S7.
Article
7. Ishikawa M, Sekizuka E, Krischek B, Sure U, Becker R, Bertalanffy H. Role of nitric oxide in the regulation of spinal arteriolar tone. Neurosurgery. 2002. 50:371–377.
Article
8. Matsumoto T, Tamaki T, Kawakami M, Yoshida M, Ando M, Yamada H. Early complications of high-dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury. Spine. 2001. 26:426–430.
Article
9. Nesathruai S. Steroids and spinal cord injury: revisiting NASCIS 2 and NASCIS 3 trials. J Trauma. 1998. 45:1088–1093.
10. Peter Vellman W, Hawkes AP, Lammertse DP. Administration of corticosteroids for acute spinal cord injury: the current practice of trauma medical directors and emergency medical system physician advisors. Spine. 2003. 28:941–947.
11. Sekhon LH, Fehlings MG. Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine. 2001. 24:Suppl 24. S2–S12.
Article
12. Soy O, Aslan O, Uzun H, et al. Time-level relationship for nitric oxide and the protective effects of aminoguanidine in experimental spinal cord injury. Acta Neurochir (Wien). 2004. 146:1329–1335.
Article
13. Tarlov IM. Acute spinal cord compression paralysis. J Neurosurg. 1972. 36:10–20.
Article
14. Tator CH. Update on the pathophysiology and pathology of acute spinal cord injury. Brain Pathol. 1995. 5:407–413.
Article
15. Yang JY, Riew KD. Agonist for the control of apoptosis through the study of cytokine expression after spinal cord injury in rats. J Korean Orthop Assoc. 2007. 42:106–114.
16. Yang JY, Lee JK, Kim YM, Kim KC, Lee CH, Kim HS. The changes of nitric oxide synthase after spinal cord injury according to the age in rats. J Korean Orthop Assoc. 2006. 41:703–710.
17. Yang JY, Lee JK, Kim KT, Lee HH, Byun BN, Ahn SH. The expression and function of the tumor necrosis factor receptor I (TNFRI), TNFRII, and X-linked inhibitor of apoptosis genes after spinal cord injury in rats. J Korean Soc Spine Surg. 2004. 11:14–23.
Article
18. Yang JY, Lee JK, Kim SB. The changes of apoptosis according to the time of administration of methylprednisolone after spinal cord injury in rats. The Spine J. 2006. 6:5s. 23s.
19. Zhang F, Iadecola C. Temporal characteristics of the protective effect of aminoguanidine on cerebral ischemic damage. Brain Res. 1998. 802:104–110.
Article